-+ 0.00%
-+ 0.00%
-+ 0.00%

Supernus Q3 2026 net earnings swing to $20.91 million from year-earlier loss

PUBT·10/29/2026 20:32:46
Supernus Q3 2026 net earnings swing to $20.91 million from year-earlier loss
  • Supernus Pharmaceuticals swung to third-quarter 2026 net earnings of $20.9 million from a year-earlier loss.
  • Total revenues rose 18% year over year to $226.8 million.
  • The merger with Indivior is expected to close November 2, 2026, targeting $125 million in annual cost synergies.
  • Full-year 2026 stand-alone total revenues guidance increased to $875 million–$900 million; the outlook will no longer apply once the merger closes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Supernus Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610291605PRIMZONEFULLFEED9856510) on October 29, 2026, and is solely responsible for the information contained therein.